Introduction
============

Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as "pain caused by a lesion or disease of the somatosensory nervous system". It is a clinical description rather than a clinical diagnosis which would require "a demonstrable lesion or disease that satisfies the established neurological diagnostic criteria".[@b1-jpr-11-1307] In the general population, 6%--8% suffer from neuropathic pain.[@b2-jpr-11-1307]--[@b4-jpr-11-1307] Nociceptive pain is defined as "pain that arises from actual or threatened damage to non-neural tissue and is due to activation of nociceptors". This allows us to distinguish between patients with neuropathic pain (classification based on an abnormally functioning somatosensory nervous system) and nociceptive pain (classification based on a normally functioning somatosensory nervous system). Because co-existence of both conditions (mixed-pain condition) is frequently observed in daily clinical practice, La Cesa et al suggest using the presence or absence of a neuropathic pain component (absent or present NePC).[@b5-jpr-11-1307] NePC assessment is based on history taking, clinical examination, and (quantitative) sensory testing and includes bedside examination (BSE).[@b6-jpr-11-1307]--[@b8-jpr-11-1307] Clinical examination alone can never offer proof that a specific pain is of neuropathic origin, but it provides supporting evidence for alterations in the functioning of the nervous system.[@b6-jpr-11-1307] According to the IASP neuropathic pain special interest group (NeuPSIG), abnormal sensory findings should be neuroanatomically plausible when an NePC is present, and the sensory signs should be associated with the neuroanatomically plausible distribution compatible with an underlying relevant lesion or disease of the somatosensory nervous system.[@b9-jpr-11-1307],[@b10-jpr-11-1307] As part of a bedside clinical neurological examination, sensory testing can identify negative sensory symptoms such as hyperalgesia or hypoesthesia and/or positive sensory symptoms such as allodynia and hyperalgesia.[@b5-jpr-11-1307] According to Haanpää et al,[@b6-jpr-11-1307] BSE can possibly identify where the pathology causing the pain can be found in the central nervous system.

In the last decades, quantitative sensory testing (QST) has complemented traditional neurological BSE tests. QST uses psychophysical tests defined as stimuli with predetermined physical properties based on specific measurement protocols for the analysis of somatosensory aberrations.[@b11-jpr-11-1307]--[@b13-jpr-11-1307] QST measures responses to sensory stimuli and can be used to assess somatosensory system function,[@b11-jpr-11-1307],[@b12-jpr-11-1307] the measurement of the altered peripheral and/or central pain sensitivity,[@b14-jpr-11-1307]--[@b16-jpr-11-1307] and descending pain modulation.[@b17-jpr-11-1307],[@b18-jpr-11-1307] QST is thought to offer greater precision and reliability when assessing somatosensory system functionality than a standard BSE[@b19-jpr-11-1307],[@b20-jpr-11-1307] because of the use of controlled automated devices. There is evidence that QST improves the diagnostic process of patients with pain, and that it may be valuable when monitoring for a specific anti-neuropathic treatment.[@b21-jpr-11-1307],[@b22-jpr-11-1307] Moreover, an altered pain modulation can be assessed on the basis of signs and symptoms of peripheral and central sensitization[@b17-jpr-11-1307],[@b23-jpr-11-1307]--[@b25-jpr-11-1307] and by the use of conditioned pain modulation (CPM).[@b19-jpr-11-1307],[@b26-jpr-11-1307] CPM is a physiological phenomenon that can be used to assess the quality of the endogenous pain inhibitory pathway, also known as the "pain inhibits pain" phenomena.[@b27-jpr-11-1307] The Nijmegen--Aalborg screening QST (NASQ)[@b15-jpr-11-1307],[@b16-jpr-11-1307],[@b24-jpr-11-1307],[@b28-jpr-11-1307] measures pain and central pain processing under standardized conditions using defined stimuli and experienced intensity ratings. There is no "gold standard" for the diagnosis of NePC, and the association between NePC and BSE/NASQ has not yet been fully evaluated. There is a need for studies to more objectively identify the presence of an NePC and to assess the diagnostic accuracy of BSE and NASQ for NePC.[@b5-jpr-11-1307]

The objective of this study was to assess the potential association between clinically diagnosed absent or present NePC and BSE and NASQ in patients with chronic (≥3 months) low back and leg pain (LBLP) or with neck shoulder arm pain (NSAP) radiating into the leg(s) or arm(s), or in patients with chronic pain due to suspected peripheral nerve damage (sPND).

Methods
=======

This study is based on a cross-sectional, observational research design to generate new insights into the clinical assessment of NePC. It is a sub-analysis of a study approved by the medical and ethical review board Committee on Research Involving Human Subjects, region Arnhem-Nijmegen, Nijmegen, the Netherlands, dossier number: 2008/348; NL 25343.091.08.

In the original study conducted between October 2009 and June 2013, we validated the Dutch PainDETECT[@b29-jpr-11-1307] and the DN4.[@b30-jpr-11-1307],[@b31-jpr-11-1307] The PainDETECT[@b32-jpr-11-1307] and the DN4[@b33-jpr-11-1307] were both developed to screen for the presence of neuropathic pain. The patient self-administered PainDETECT is a simple screening tool with no need for physical examination. The instrument consists of one item about the pain course pattern, one about radiating pain, and seven questions about the gradation of pain. The clinician-administered DN4 consists of a total of 10 items with yes/no answers. It is divided into two questions (symptoms) and two physical examination tests (signs). The two sign items were incorporated in the sensory examination part of the standardized assessment form.[@b28-jpr-11-1307] The protocol was registered in the Dutch National Trial Register: NTR 3030 and published by Timmerman et al.[@b28-jpr-11-1307] Patients provided written informed consent after screening, but before participation in the study.

Participants
------------

We recruited patients as part of the Dutch validation studies concerning the PainDETECT and the DN4. Inclusion criteria were male and female adult patients aged over 18 years with chronic (≥3 months) LBLP or NSAP, or patients with chronic pain due to sPND. We excluded patients suspected for or diagnosed with malignancy; compression fractures; patients with diffuse pains such as fibromyalgia or ankylosing spondylitis; severe mental illness; chronic alcoholism or substance abuse; inability to fill in the questionnaire adequately; or incapable of understanding the Dutch language.

Pain classification
-------------------

Classification of patients' pain was based on the NeuPSIG guidelines on neuropathic pain assessment.[@b6-jpr-11-1307] Pain classification was performed consecutively but blinded for the outcome on the same patient independently by two physicians working in different compositions, and then categorized into three groups: "absent NePC", "present NePC" where both physicians were in agreement, or "undetermined NePC" in cases where they did not agree. A full medical history and clinical examination including sensory BSE was taken[@b6-jpr-11-1307],[@b7-jpr-11-1307],[@b21-jpr-11-1307],[@b28-jpr-11-1307],[@b34-jpr-11-1307] and considered as the gold standard for NePC diagnosis.

Bedside examination
-------------------

Multicenter recruitment took place in the Netherlands in three academic pain centers and in four non-academic pain centers. A standardized BSE[@b28-jpr-11-1307] was independently performed by two physicians during the validation study for the two neuropathic pain screening tools. Prior to the study, the physicians were trained in the standardized evaluation of patients with chronic pain using specific modalities such as touch, pin prick, pressure, cold, heat, vibration, and temporal summation. The location indicated by the patient as having maximum pain was compared with the mirrored location on the contralateral side. When the pain had a double-sided character, a location without pain but as close as possible to the original mirror site was tested for comparison. Patients were asked the following: 1) is a sensation present? 2) is the sensation unpleasant? or 3) is the sensation painful? (all scored as yes, no, or unclear) The outcome was noted by the physician on the standardized assessment form.[@b28-jpr-11-1307] The following tests were performed consecutively on each patient independently by two physicians: 1) mechanical static allodynia via blunt pressure with a finger at a force that normally does not evoke pain; 2) dynamic mechanical allodynia via stroking the skin with a Soft Brush (SENSElab™, Brush-05, Somedic AB, Hörby, Sweden), 2a) one movement of 1--2 centimeter and 2b) three movements of 1--2 centimeters (wind-up response); 3) mechanical pinprick allodynia via touch of the skin with 3a) a plastic safety pin and 3b) a Von Frey hair (TOUCH TEST®, 5.07, 10.0 g, North Coast Medical Inc., Gilroy, CA, USA); 4) heat allodynia by use of TipTherm® (TipTherm, Brüggen, Germany) in a baby-bottle warmer (ISI mini Baby Bottle Warmer, Assen, the Netherlands) set at 45 degrees Celsius; 5) cold allodynia with an ice cube placed on the skin for 2 seconds; and 6) vibration with a tuning fork (128 Hz; Medipharchem, Wormerveer, the Netherlands) applied to joint, bone, or soft tissue in the region of the pain.

Nijmegen--Aalborg screening QST
-------------------------------

Patients for the additional NASQ part of the study were recruited in one academic pain center and two non-academic pain centers. After screening in the clinical department, patients were asked to participate. The NASQ was performed in a random sub-sample of 20% of the patient population (LBLP, NSAP, and sPND) by a trained and experienced researcher (HT).[@b28-jpr-11-1307] The NASQ paradigm[@b15-jpr-11-1307],[@b16-jpr-11-1307],[@b24-jpr-11-1307],[@b28-jpr-11-1307] was used as screening protocol. The NASQ screens for changes in pain processing based on a systematic mechanism-oriented approach.[@b16-jpr-11-1307] It maps pain sensitivity at multiple sites by measuring the responses (ie, painful sensations) evoked by mechanical and electrical non-invasive stimuli, and measures the patient's capacity to modulate pain using the CPM. Instructions were standardized and read to each patient from an instruction sheet.

Pressure pain threshold (PPT) test
----------------------------------

A pressure algometer (Somedic AB) was used to measure PPTs bilaterally at each location, expressed in kilo Pascal: thenar (middle part), musculus trapezius pars median (middle part), musculus rectus femoris (15 cm above patella), and musculus abductor hallucis (middle part). In addition to the analysis with an average value over these eight measurement points, we performed additional analyses in the four central measurement points: musculus trapezius pars median (both sides) and musculus rectus femoral (both sides), and the four peripheral measurement points: thenar (both sides) and m. abductor hallucis (both sides).

Electrical pain thresholds
--------------------------

The QST-3 device (JNI Biomedical ApS, Klarup, Denmark) was used to measure electrical pain thresholds (EPTs) on the left and right body side. Measurement locations were the musculus trapezius pars median (middle part) and the musculus rectus femoris (20 cm above patella). Thresholds were assessed and expressed in milli-Ampère. EPTs were measured as electrical pain detection threshold (EPDT) when the current started to feel pain, and as electrical pain tolerance threshold (EPTT) when the current was as high as the patient could tolerate.

CPM response
------------

We assessed CPM[@b17-jpr-11-1307],[@b27-jpr-11-1307] via the PPT (CPMp) and the EPT (CPMe) on the m. rectus femoris contralateral to the dominant hand. The noxious stimulus (conditioning stimulation) was to immerse the dominant hand to the wrist in a bucket filled with water and ice cubes (ice water bucket \[IWB\] test).[@b25-jpr-11-1307] The patient was instructed to "keep the hand in the water for as long as possible, until the moment that the sensation becomes unbearable and you want to stop directly". Pain was recorded every 10 seconds on the numeric rating scale. The duration of the immersion (with a maximum of 180 seconds) was recorded and the pain intensity at the end of the immersion was also registered. The PPT and the EPT were then assessed again on the contralateral m. rectus femoris. The response was calculated by subtracting the outcome of the pre-measurement from the outcome of the post-measurement. The CPM values were calculated using the following formulas: $$\begin{array}{l}
{CPMp = (\lbrack PPT_{post} - PPT_{pre}\rbrack/PPT_{pre})*100} \\
{CPMe = (\lbrack EPT_{post} - EPT_{pre}\rbrack/EPT_{pre})*100} \\
\end{array}$$

CPM was regarded as "positive" when the outcome of the calculation was equal or higher than zero and negative when it was below zero.

Data
----

All data were collected on paper from the patients and the physicians and stored at Radboudumc, Nijmegen, the Netherlands. Data management and monitoring were performed using MACRO (MACRO, version 4.1.1.3720, InferMed, London, UK). Data analysis and statistics were performed using Statistical Package for the Social Sciences (SPSS version 20.0, SPSS Inc., Chicago, IL, USA).

Statistical methods
-------------------

Qualitative variables are presented as frequencies and percentages. Quantitative variables are presented as mean and SD or as median and interquartile range. The chi-square test was used to test for significant differences between nominal outcome data. Cramér's *V* was used as a measure of association between two nominal variables, giving a value between 0 and 1. Mann--Whitney *U*-test was used to test the differences between present and absent NePC. Kruskal--Wallis test was used to study differences between the three (absent NePC, present NePC, and undetermined) groups. We used Cohen's Kappa and the percentage of pair wise agreement to determine the agreement between the BSE between the patient's first and second assessment. A two-tailed *p*-value below 0.05 was considered statistically significant.

Results
=======

In total, 330 patients with chronic LBLP, NSAP, or sPND were assessed for eligibility. Two patients did not provide informed consent prior to inclusion in the study. Thirty-seven patients were excluded because of not meeting the inclusion and exclusion criteria (n=13); not returning the baseline questionnaires (n=16), and missing pain classification by one physician (n=5) or both physicians (n=3).

BSE was performed in this study in 291 patients by 62 different physicians from seven hospitals. The present NePC group (n=170) consisted of 75 patients with LBLP, 23 patients with NSAP, and 72 patients with sPND. The absent NePC group (n=58) consisted of 28 patients with LBLP, 18 patients with NSAP, and 12 patients with sPND. For the undetermined group (n=63), the numbers were 29, 10, and 24, respectively (see [Figure 1](#f1-jpr-11-1307){ref-type="fig"} and [Table 1](#t1-jpr-11-1307){ref-type="table"}).

The NASQ was performed in a total of 69 patients. Patients were excluded after the NASQ measurements were made: not fulfilling the inclusion and exclusion criteria (n=9) or a missing assessment by a second physician (n=2). Finally, a total of 58 patients (56 Dutch natives, 1 German native, and 1 of Chinese/Indonesian origin) were included in the analysis: 25 with LBLP, 25 with NSAP, and 8 with sPND. After NePC assessment by the physicians, 16 patients were classified as absent NePC, 29 with present NePC, and 13 patients with an undetermined outcome. The absent NePC group, present NePC group, and undetermined group had 4, 14, and 7 patients with LBLP; 12, 7, and 5 patients with NSAP; and 0, 7, and 1 patient(s) with sPND, respectively (see [Figure 1](#f1-jpr-11-1307){ref-type="fig"} and [Table 1](#t1-jpr-11-1307){ref-type="table"}).

In [Tables 2](#t2-jpr-11-1307){ref-type="table"} and [S1](#SD1-jpr-11-1307){ref-type="supplementary-material"}, we have shown the outcome of the BSE based on the inter-physician agreement on the existence of an NePC. In the first assessment by the physician, the answers on the question "is there a sensation (yes, no, unclear) during testing for heat, cold, touch (brush 3 times), and pricking (both safety pin and von Frey hair)" were significantly lower (*p*\<0.05) for yes in the group with present NePC compared to the absent NePC group. In the second assessment, the scores for the question "is there a sensation (yes, no, unclear) of heat, cold, touch, (only brush 1 time), and pricking (von Frey hair only)" were significantly lower (*p*\<0.05) for yes in the group with present NePC with a lower percentage of "yes" compared to the absent NePC. The scores for the questions "is the touch with a finger unpleasant?" and "is touch with a brush unpleasant?" were higher for the second assessment for the group with present NePC (*p*=0.049 and *p*=0.006, respectively). "Painful for touch with a finger" was more common in patients with present NePC (*p*=0.026) in the second assessment. "Wind-up" was more common in patients with present NePC compared to the patients with absent NePC (first assessment *p*=0.056; second assessment *p*=0.029). In [Table S1](#SD1-jpr-11-1307){ref-type="supplementary-material"}, we have shown the outcome of the BSE based on the inter-physician agreement for the occurrence of NePC for patients with LBLP, NSAP, and sPND.

The outcomes of the NASQ measurements related to physician agreement for the existence of NePC are presented in [Table 3](#t3-jpr-11-1307){ref-type="table"}. No significant difference was detected for pressure, EPDT, EPTT, and duration of submerging the hand in the IWB between the absent, present, and undetermined NePC groups. We found no congruency between the CPMp and the CPMe. When basing the CPM classification on pressure values, the significance disappeared for the outcome of the CPM test based on electricity values (response *p*=0.440, CPM-value *p*=0.374). This was also true when the CPM electricity test outcome was used to analyze the response and CPM value for pressure (*p*=0.728 and *p*=0.810, respectively). Moreover, in the IWB test, we found no significant differences regarding the duration (latency) of submerging the hand between the positive and negative CPM test for both the pressure and electricity conditions (*p*=0.120 and *p*=0.711, respectively).

Discussion
==========

The aim of this study was to assess the potential association between a clinically diagnosed absent or present NePC, BSE, and NASQ in patients with chronic pain. BSE revealed minor differences, with a low association between patients with present NePC and patients with absent NePC following independent clinical NePC assessment by two independent physicians, while none were found with NASQ.

Bedside examination
-------------------

We used BSE based on mechanical and thermal testing procedures, performed by two physicians independently and blinded for the results of the other.[@b28-jpr-11-1307] The added value of BSE is that it gives insights into the pathology and the localization of the nerve lesion or disease causing the pain.[@b6-jpr-11-1307],[@b7-jpr-11-1307],[@b35-jpr-11-1307],[@b36-jpr-11-1307] The BSE results showed statistical significant differences between patients with absent NePC and patients with present NePC. BSE revealed that the sensation of heat, cold, wind-up response (with a brush, three times), pricking with a safety pin, and pricking with a von Frey hair was less common in patients with a present NePC than in those with an absent NePC. In addition, wind-up response occurred more often in patients with present NePC than in those with absent NePC.

Screening QST
-------------

We used the NASQ to assess the altered pain processing, including changes in function of endogenous pain modulation as a secondary test battery.[@b15-jpr-11-1307],[@b28-jpr-11-1307] The NASQ test protocol has standardized instructions, an important prerequisite to ensure reliability of the measurements.[@b20-jpr-11-1307],[@b37-jpr-11-1307] We found no differences between patients with absent and present NePC regarding PPTs, electrical pain (tolerance) thresholds, and CPM outcomes (number of positive and negative CPM outcomes, the response, the CPM value, and the latency times when submerging the hand in ice water). Granovsky[@b38-jpr-11-1307] reported that patients with chronic neuropathic pain express a less efficient (negative) CPM. In our study, we could not confirm this when comparing patients with LBLP, NSAP, or sPND with and without NePC. As suggested by Graven-Nielsen and Arendt-Nielsen,[@b39-jpr-11-1307] lower PPTs may be indicative for central sensitization. We also could not find any differences in the pain thresholds of patients with and without NePC. Moreover, a difference in CPM may also suggest a central dysfunction. However, based on our results, we cannot state that there are signs of central sensitization or altered central pain processing as might be suspected because of lower pain thresholds for pressure pain or an impaired CPM, because we did not include age, sex, and education matched controls, which would be necessary to draw these higher level conclusions.

Limitations
-----------

We would have preferred to use the German Research Network on Neuropathic Pain (DFNS)[@b11-jpr-11-1307],[@b12-jpr-11-1307] to BSE because of the standardization of the complete test procedure (written test instructions, application of the test stimuli, and data analyses).[@b12-jpr-11-1307],[@b40-jpr-11-1307] However, due to time constraints in a patient care setting, it was not possible and preferable to use such a research test battery. Moreover, in simulating daily clinical practice, fulfilling the DFNS protocol is not applicable due to instrument availability and the associated costs in all participating sites. BSE as used in our study is easy to learn (one training session before execution of the study) and to carry out in daily clinical practice. Another strength of the study is that we included a range of locations and a large group of patients with chronic pain arising from different origins, which is comparable to patients in a daily clinical (pain) practice. A limitation of the BSE examination is that we only used the question "Is there a sensation?" This may have led to a lower estimation of the outcomes because the patients and/or physicians may have interpreted the question was only being related to the presence of hypoesthesia, hypoalgesia, or analgesia (answer "no": negative signs) rather than assessing the presence of hyperalgesia or allodynia positively (answer "yes"). In a following study, we will change this to a more open question that can be interpreted both ways. We did not use verbal standardized instructions, although all participating professionals were trained in a standardized way and so this is another possible limitation of our BSE method. This may have led to differences in the questioning by the physicians, thereby influencing the patients' answers and the test outcome. The order of the BSE tests was not randomized and so there may be an order effect resulting from the previously performed test. Moreover, both physicians tested the same patient directly following each other. Although the second physician was not aware of the first results, this may have also influenced our results. Furthermore, there was no correction for multiple testing while several statistical analyses were performed. Because of this, the results must be interpreted with caution.

Another possible limitation is the fact that we only included a small group of patients with chronic pain measured via NASQ; 8 patients with sPND. This may have affected our outcome because they have a different disease origin compared to patients with LBLP or NSAP. For future NASQ research, we would suggest collecting normative data preferably matched for age, sex, and education level. With these data, the value of NASQ for clinical monitoring disease progression and the response of individual patients on treatment can be evaluated.

Conclusion
==========

Using a standardized BSE to assess sensory dysfunction indicating the presence or absence of an NePC appears to be preferable compared to the NASQ paradigm in patients with chronic pain. However, further development of both assessments is desirable. The BSE should be adapted to detect sensory differences between absent and present NePC; the NASQ paradigm should be able to measure altered pain processing and endogenous pain modulation in patients with chronic pain due to present or absent NePC. We postulate that this will lead to a greater contribution to the assessment of neuropathic components of patients' pain.

Supplementary material
======================

###### 

Bedside examination outcome based on inter physician agreement on the presence of an NePC for the total group and for patients with LBLP, NSAP, or sPND separately

                             First assessment   Second assessment   Agreement between physicians                                                                                                                     
  -------------------------- ------------------ ------------------- ------------------------------ ---- ----- ----------- ----------- ------- ----- ----- ---- ----- ----------- ----------- ----------- ----------- ----------
  Touch (finger)                                                                                                                                                                                                     
   Sensation                 **Total**          290                 58                             95   169   95          0.964       0.003   289   58    97   168   96          0.965       0.003       0.177       93.3
  LBLP                       131                28                  100                            74   99    0.536       0.061       132     28    100   75   96    0.283       0.106       −0.015      96.0        
  NSAP                       51                 18                  89                             23   91    0.796       0.040       50      18    94    22   95    0.884       0.023       **0.787**   **97.5**    
  sPND                       108                12                  92                             72   92    1.000       0.000       107     12    92    71   97    0.344       0.104       −0.053      91.3        
   Unpleasant                **Total**          288                 57                             35   168   45          0.181       0.089   289   58    33   168   48          **0.049**   0.131       0.378       69.5
  LBLP                       130                27                  22                             74   30    0.456       0.074       132     28    25    75   28    0.761       0.030       0.242       70.3        
  NSAP                       51                 18                  44                             23   44    0.951       0.010       50      18    33    22   45    0.436       0.123       0.388       70.0        
  sPND                       107                12                  50                             71   62    0.433       0.086       107     12    50    71   69    0.198       0.141       0.318       68.3        
   Painful                   **Total**          286                 57                             28   167   37          0.215       0.083   288   57    25   168   41          **0.026**   0.149       0.315       68.8
  LBLP                       130                27                  19                             74   22    0.734       0.034       132     28    18    75   43    0.425       0.079       0.202       73.3        
  NSAP                       51                 18                  33                             23   44    0.509       0.103       50      18    28    22   41    0.386       0.137       0.297       67.5        
  sPND                       105                12                  42                             70   51    0.532       0.069       106     11    36    71   58    0.185       0.146       0.275       63.8        
  Heat                                                                                                                                                                                                               
   Sensation                 **Total**          283                 57                             91   166   68          **0.001**   0.230   287   57    91   167   66          **0.000**   0.247       **0.435**   **77.6**
  LBLP                       127                27                  96                             71   69    **0.004**   0.288       131     27    96    75   68    **0.003**   0.290       **0.579**   **84.5**    
  NSAP                       48                 18                  89                             23   74    0.230       0.188       50      18    100   22   86    0.103       0.258       0.286       82.5        
  sPND                       108                12                  83                             72   65    0.215       0.135       106     12    67    70   57    0.536       0.068       0.301       67.1        
   Unpleasant                **Total**          283                 57                             16   166   16          0.707       0.056   287   57    16   167   21          0.396       0.057       0.319       79.9
  LBLP                       127                27                  22                             71   8     0.153       0.196       131     27    19    75   13    0.514       0.065       0.117       79.4        
  NSAP                       48                 18                  6                              23   9     0.702       0.060       50      18    6     22   18    0.230       0.190       0.231       87.5        
  sPND                       108                12                  17                             72   25    0.742       0.084       106     12    25    70   30    0.725       0.039       **0.424**   **76.8**    
   Painful                   **Total**          283                 57                             7    166   9           0.626       0.065   287   57    12   167   14          0.775       0.019       0.258       90.0
  LBLP                       127                27                  7                              71   3     0.494       0.120       131     27    11    75   8     0.625       0.048       −0.057      87.6        
  NSAP                       48                 18                  6                              23   9     0.702       0.060       50      18    6     22   14    0.397       0.134       0.286       90.0        
  sPND                       108                12                  8                              72   15    0.741       0.084       106     12    25    70   20    0.693       0.044       0.355       80.5        
  Cold                                                                                                                                                                                                               
   Sensation                 **Total**          275                 55                             93   165   75          **0.016**   0.194   284   58    93   168   75          **0.003**   0.196       0.320       77.6
  LBLP                       130                28                  96                             74   80    **0.038**   0.205       131     28    96    75   79    **0.031**   0.213       **0.458**   **85.3**    
  NSAP                       43                 15                  87                             22   86    0.979       0.004       50      18    100   22   95    0.360       0.145       0.302       89.2        
  sPND                       102                12                  92                             69   65    0.186       0.204       103     12    75    71   65    0.489       0.076       0.148       62.5        
   Unpleasant                **Total**          274                 55                             2    164   12          0.052       0.164   284   58    7    168   11          0.338       0.064       0.333       87.6
  LBLP                       129                28                  4                              73   10    0.489       0.119       131     28    7     75   5     0.727       0.034       0.357       91.1        
  NSAP                       43                 15                  0                              22   9     0.230       0.197       50      18    0     22   18    0.057       0.302       **0.641**   **94.6**    
  sPND                       102                12                  0                              69   16    0.294       0.174       103     12    17    71   15    0.918       0.011       0.217       80.0        
   Painful                   **Total**          273                 54                             0    164   5           0.178       0.126   284   58    2    168   6           0.197       0.086       **0.477**   **95.4**
  LBLP                       129                28                  0                              73   0     0.534       0.062       131     28    4     75   1     0.464       0.072       −0.007      97.0        
  NSAP                       42                 14                  0                              22   5     0.418       0.135       50      18    0     22   14    0.103       0.258       **0.478**   **94.4**    
  sPND                       102                12                  0                              69   10    0.462       0.138       103     12    0     71   8     0.296       0.115       **0.582**   **93.8**    
  Touch (brush 1 time)                                                                                                                                                                                               
   Sensation                 **Total**          288                 58                             93   167   81          0.104       0.142   286   57    93   167   79          **0.017**   0.160       0.264       79.6
  LBLP                       130                28                  100                            73   90    0.089       0.169       132     28    100   75   88    0.055       0.189       0.187       88.1        
  NSAP                       51                 18                  89                             23   96    0.409       0.129       48      17    100   22   86    0.113       0.254       0.278       89.7        
  sPND                       107                12                  83                             71   68    0.533       0.123       106     12    67    70   67    0.974       0.004       0.178       64.2        
   Unpleasant                **Total**          288                 58                             2    167   7           0.156       0.095   287   57    2    168   7           0.132       0.100       0.384       93.7
  LBLP                       130                28                  4                              73   6     0.826       0.022       132     28    0     75   3     0.383       0.086       0.385       97.0        
  NSAP                       51                 18                  0                              23   9     0.200       0.200       48      17    0     22   18    0.063       0.297       0.374       62.3        
  sPND                       107                12                  0                              71   10    0.256       0.125       106     12    8     71   8     0.989       0.001       0.375       90.2        
   Painful                   **Total**          288                 58                             0    167   2           0.234       0.079   287   57    0    168   4           0.148       0.096       0.387       97.3
  LBLP                       130                28                  0                              73   1     0.534       0.062       132     28    0     75   3     0.383       0.086       −0.013      97.0        
  NSAP                       51                 18                  0                              23   0     ---         ---         48      17    0     22   5     0.373       0.143       0.000       97.4        
  sPND                       107                12                  0                              71   4     0.468       0.080       107     12    0     71   4     0.468       0.080       **0.654**   **97.6**    
  Touch (brush 3 times)                                                                                                                                                                                              
   Sensation                 **Total**          290                 58                             97   169   85          **0.021**   0.153   289   58    91   169   80          **0.055**   0.127       0.303       82.7
  LBLP                       132                28                  100                            75   96    0.283       0.106       132     28    100   75   93    0.161       0.138       0.222       94.2        
  NSAP                       51                 18                  89                             23   96    0.409       0.129       50      18    100   22   86    0.103       0.258       0.279       90.0        
  sPND                       107                12                  100                            71   70    **0.029**   0.239       107     12    58    72   65    0.642       0.051       0.190       65.1        
   Unpleasant                **Total**          291                 58                             2    170   7           0.130       0.100   290   58    0    169   12          **0.006**   0.182       0.197       89.4
  LBLP                       132                28                  4                              75   5     0.711       0.036       132     28    0     75   8     0.123       0.152       0.136       91.3        
  NSAP                       51                 18                  0                              23   87    0.200       0.200       50      18    0     22   23    **0.031**   0.342       0.304       90.0        
  sPND                       108                12                  0                              72   8     0.299       0.113       108     12    0     72   13    0.195       0.141       0.198       86.9        
   Painful                   **Total**          291                 58                             0    170   2           0.308       0.067   290   58    0    169   5           0.092       0.112       0.351       96.9
  LBLP                       132                28                  0                              75   3     0.383       0.086       132     20    0     75   4     0.283       0.106       0.386       97.1        
  NSAP                       51                 18                  0                              23   0     ---         ---         50      18    0     22   5     0.360       0.145       0.000       97.5        
  sPND                       108                12                  0                              72   1     0.681       0.045       108     12    0     72   6     0.403       0.091       0.388       96.4        
   Wind-up                   **Total**          284                 56                             0    167   8           0.056       0.161   276   50    0    164   12          **0.029**   0.182       0.188       87.1
  LBLP                       131                28                  0                              75   7     0.304       0.152       125     26    0     71   7     0.310       0.155       0.296       91.8        
  NSAP                       48                 16                  0                              22   9     0.215       0.201       44      12    0     22   5     0.290       0.270       0.145       87.1        
  sPND                       105                12                  0                              70   10    0.468       0.136       107     12    0     71   15    0.143       0.161       0.116       81.5        
  Pricking (safety pin)                                                                                                                                                                                              
   Sensation                 **Total**          289                 58                             95   168   79          **0.006**   0.183   290   58    91   169   82          0.080       0.116       0.240       79.6
  LBLP                       132                28                  100                            75   85    **0.032**   0.211       132     28    100   75   92    0.123       0.152       0.046       85.4        
  NSAP                       51                 18                  94                             23   91    0.702       0.060       50      18    100   22   95    0.360       0.145       **0.481**   **95.0**    
  sPND                       106                12                  25                             71   35    0.489       0.079       108     12    58    72   67    0.574       0.061       0.176       64.6        
   Unpleasant                **Total**          290                 58                             19   169   31          0.180       0.123   290   58    24   169   31          **0.298**   0.069       0.357       73.4
  LBLP                       132                28                  21                             75   31    0.519       0.113       132     28    32    75   32    0.989       0.001       **0.456**   **76.7**    
  NSAP                       51                 18                  11                             23   17    0.572       0.088       50      18    11    22   32    0.119       0.247       0.106       72.5        
  sPND                       107                12                  25                             71   35    0.489       0.076       108     12    25    72   31    0.697       0.043       0.308       69.9        
   Painful                   **Total**          290                 58                             10   169   20          0.227       0.114   290   58    16   169   21          **0.388**   0.057       0.286       78.3
  LBLP                       132                28                  14                             75   15    0.826       0.061       132     28    18    75   17    0.950       0.006       0.265       79.6        
  NSAP                       51                 18                  0                              23   13    0.111       0.249       50      18    11    22   27    0.204       0.201       0.082       77.5        
  sPND                       107                12                  17                             71   27    0.457       0.082       108     12    17    72   22    0.664       0.047       0.364       77.1        
  Pricking (von Frey hair)                                                                                                                                                                                           
   Sensation                 **Total**          289                 58                             91   168   68          **0.003**   0.230   288   57    91   169   68          **0.001**   0.229       **0.455**   **79.0**
  LBLP                       132                28                  96                             75   82    **0.045**   0.245       132     28    96    75   75    **0.013**   0.245       0.291       77.7        
  NSAP                       51                 18                  94                             23   91    0.702       0.060       50      18    100   22   91    0.189       0.208       **0.787**   **97.5**    
  sPND                       106                12                  75                             70   54    0.180       0.148       106     11    64    72   54    0.556       0.065       **0.423**   **71.6**    
   Unpleasant                **Total**          289                 58                             7    168   14          0.228       0.114   288   58    16   167   20          0.475       0.048       0.329       81.6
  LBLP                       132                28                  4                              75   16    0.353       0.142       131     28    18    74   14    0.580       0.055       0.171       81.4        
  NSAP                       51                 18                  0                              23   13    0.111       0.249       50      18    11    22   32    0.119       0.247       **0.437**   **85.0**    
  sPND                       106                12                  25                             70   17    0.752       0.083       107     12    17    71   23    0.648       0.050       **0.410**   **80.2**    
   Painful                   **Total**          289                 58                             3    168   7           0.473       0.081   288   58    12   167   10          0.590       0.036       **0.402**   **90.6**
  LBLP                       132                28                  4                              75   4     0.823       0.062       131     28    14    74   8     0.349       0.093       0.292       90.2        
  NSAP                       51                 18                  0                              23   8     0.111       0.249       50      18    6     22   14    0.397       0.134       **0.531**   **92.5**    
  sPND                       106                12                  8                              70   7     0.909       0.048       107     12    17    71   10    0.483       0.077       **0.450**   **90.1**    
  Vibration                                                                                                                                                                                                          
   Sensation                 **Total**          291                 58                             79   170   69          0.060       0.157   288   58    81   167   66          0.089       0.147       0.358       73.3
  LBLP                       132                28                  71                             75   68    0.218       0.172       131     28    71    74   58    0.217       0.122       **0.446**   **74.5**    
  NSAP                       51                 18                  89                             23   78    0.369       0.140       50      18    94    22   91    0.673       0.067       0.136       82.5        
  sPND                       108                12                  83                             72   68    0.284       0.117       107     12    83    71   66    0.484       0.132       0.242       67.5        
   Unpleasant                **Total**          290                 57                             5    170   10          0.528       0.075   290   58    5    169   11          0.275       0.107       0.225       85.4
  LBLP                       132                28                  4                              75   8     0.571       0.105       132     28    0     75   7     0.304       0.152       0.362       91.3        
  NSAP                       50                 17                  6                              23   9     0.738       0.053       50      18    6     22   23    0.130       0.239       0.133       87.2        
  sPND                       108                12                  8                              72   13    0.838       0.065       108     12    17    72   13    0.855       0.061       0.155       79.8        
   Painful                   Total              291                 58                             3    170   8           0.517       0.076   290   58    0    169   7           0.114       0.138       **0.435**   **93.0**
  LBLP                       132                28                  4                              75   9     0.720       0.080       132     28    0     75   3     0.562       0.106       0.380       94.2        
  NSAP                       51                 18                  0                              23   13    0.111       0.249       50      18    0     22   14    0.103       0.258       **0.640**   **95.0**    
  sPND                       108                12                  8                              72   8     0.919       0.045       108     12    0     72   8     0.299       0.113       0.381       90.5        

**Notes:** Classification for the existence of NePC is based on the physicians' assessment of the patient. n, the number of patients; %, the percentage of positive answers (yes) on the questions; Sensation, Is there a sensation?; Unpleasant, Is the sensation unpleasant?; Painful, Is the sensation painful?; *p*-value, *p* value for statistical significant difference between groups (outcome of chi-square test, *p*≤0.05). Bold values are statistically significant (*p*≤0.05).

**Abbreviations:** NePC, neuropathic pain component; LBLP, low back and leg pain; NSAP, neck shoulder arm pain; sPND, suspected peripheral nerve damage; V, value of Cramér's V; K, Kappa value; PA, percentage of agreement.
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![Flow diagram for the performance of the BSE and NASQ in patients with chronic pain with respect to the physicians' assessment.\
**Notes:** n, number of patients in analysis; Present NePC, NePC is present; Undetermined, both physicians disagree with each other about the presence of a NePC; Absent NePC, no NePC is present.\
**Abbreviations:** LBLP, low back and leg pain; NSAP, neck shoulder arm pain; sPND, suspected peripheral nerve damage; BSE, bedside examination; NePC, neuropathic pain component; NASQ, Nijmegen--Aalborg screening quantitative sensory testing.](jpr-11-1307Fig1){#f1-jpr-11-1307}

###### 

Sociodemographic characteristics for the patients included in the BSE and the NASQ examination related to the physicians' agreement for the existence of an NePC

                                     Total group                     Absent NePC                     Present NePC                    *p*-value                                          Undetermined NePC                                  *p*-value                                              
  ---------------------------------- ------------------------------- ------------------------------- ------------------------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------------------ --------------------------------------------------
  Bedside examination                n (%) Median (IQR) (N=291)      n (%) Median (IQR) (N=58)       n (%) Median (IQR) (N=170)      (N=228)                                            n (%) Median (IQR) (N=63)                          (N=291)                                                
                                                                                                                                                                                                                                                                                                  
  Sex                                Male                            98 (34%)                        25 (43%)                        56 (33%)                                           0.163[a](#tfn2-jpr-11-1307){ref-type="table-fn"}   17 (27%)                                               0.164[a](#tfn2-jpr-11-1307){ref-type="table-fn"}
  Female                             193 (66%)                       33 (57%)                        114 (67%)                                                                          46 (73%)                                                                                                  
  Age (years)                                                        57 (49;64)                      57 (50;62)                      57 (49;64)                                         0.935[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   57 (49;67)                                             0.831[c](#tfn4-jpr-11-1307){ref-type="table-fn"}
  BMI (kg/m^2^)                                                      26 (24;30)                      26 (23;30)                      26 (24;30)                                         0.943[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   27 (24;30)                                             0.688[c](#tfn4-jpr-11-1307){ref-type="table-fn"}
  Pain (NRS; 0--10)                  Current pain                    5 (3;7)                         5 (3;7)                         6 (3;7)                                            0.577[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   4 (1;7)                                                0.084[c](#tfn4-jpr-11-1307){ref-type="table-fn"}
  Worst pain                         8 (6;9)                         8 (5;9)                         8 (7;9)                         0.371[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   7 (5;8)                                            0.053[c](#tfn4-jpr-11-1307){ref-type="table-fn"}       
  Average pain                       6 (4;7)                         6 (3.5;7)                       6 (5;8)                         0.233[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   6 (3;7)                                            **0.018**[c](#tfn4-jpr-11-1307){ref-type="table-fn"}   
  Duration of pain (months)          36 (18;60)                      48 (18;60)                      31 (18;60)                      0.445[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   36 (14;60)                                         0.733[b](#tfn3-jpr-11-1307){ref-type="table-fn"}       
                                                                                                                                                                                                                                                                                                  
  **Quantitative sensory testing**   **n (%) Median (IQR) (N=58)**   **n (%) Median (IQR) (N=16)**   **n (%) Median (IQR) (N=29)**   **(N=45)**                                         **n (%) Median (IQR) (N=13)**                      **(N=58)**                                             
                                                                                                                                                                                                                                                                                                  
  Sex                                Male                            31 (53%)                        9 (56%)                         15 (52%)                                           0.771[a](#tfn2-jpr-11-1307){ref-type="table-fn"}   7 (54%)                                                0.958[a](#tfn2-jpr-11-1307){ref-type="table-fn"}
  Female                             27 (47%)                        7 (44%)                         14 (48%)                                                                           6 (46%)                                                                                                   
  Age (years)                                                        58 (52;64)                      59 (52;63)                      58 (52;64)                                         0.669[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   56 (52;65)                                             0.906[c](#tfn4-jpr-11-1307){ref-type="table-fn"}
  BMI (kg/m^2^)                                                      27 (25;31)                      26 (23;30)                      27 (25;31)                                         0.674[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   28 (25;32)                                             0.908[c](#tfn4-jpr-11-1307){ref-type="table-fn"}
  Pain (NRS; 0--10)                  Current pain                    6 (5;7)                         6 (5;7)                         6 (5;7)                                            0.887[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   5 (2;8)                                                0.613[c](#tfn4-jpr-11-1307){ref-type="table-fn"}
  Worst pain                         8 (7;9)                         8 (8;9)                         8 (7;9)                         0.740[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   8 (8;9)                                            0.706[c](#tfn4-jpr-11-1307){ref-type="table-fn"}       
  Average pain                       7 (6;7)                         7 (6;7)                         7 (6;8)                         0.424[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   7 (5;8)                                            0.567[c](#tfn4-jpr-11-1307){ref-type="table-fn"}       
  Duration of pain (months)          36 (18;78)                      52 (30;227)                     26 (18;81)                      0.069[b](#tfn3-jpr-11-1307){ref-type="table-fn"}   24 (12;57)                                         0.104[c](#tfn4-jpr-11-1307){ref-type="table-fn"}       

**Notes:** Classification for the existence of NePC is based on physicians' assessment of the patients. Absent NePC, no NePC is present; Present NePC, NePC is present; *p*-value, value for significant difference between groups (*p*≤0.05); N, total number of patients in analysis;

chi-square test;

Mann--Whitney *U*-test;

Kruskal--Wallis test. Bold values are statistically significant (*p*≤0.05).

**Abbreviations:** BSE, bedside examination; NASQ, Nijmegen--Aalborg screening quantitative sensory testing; NePC, neuropathic pain component; BMI, body mass index; NRS, numeric rating scale; median (IQR), median with interquartile range (25%--75%).

###### 

Bedside examination outcome based on inter-physician (A--B) agreement on the presence of an NePC

                                 First assessment   Second assessment   Agreement between physicians                                                                                         
  ------------------------------ ------------------ ------------------- ------------------------------ ----- ---- ----------- ------- ----- ---- ---- ----- ---- ----------- ------- ------- ------
  **Touch (finger)**                                                                                                                                                                         
  Sensation                      290                58                  95                             169   95   0.964       0.003   289   58   97   168   96   0.965       0.003   0.177   93.3
  Unpleasant                     288                57                  35                             168   45   0.181       0.089   289   58   33   168   48   0.049       0.131   0.378   69.5
  Painful                        286                57                  28                             167   37   0.215       0.083   288   57   25   168   41   **0.026**   0.149   0.315   68.8
  **Heat**                                                                                                                                                                                   
  Sensation                      283                57                  91                             166   68   **0.001**   0.230   287   57   91   167   66   **0.000**   0.247   0.435   77.6
  Unpleasant                     283                57                  16                             166   16   0.707       0.056   287   57   16   167   21   0.396       0.057   0.319   79.9
  Painful                        283                57                  7                              166   9    0.626       0.065   287   57   12   167   14   0.775       0.019   0.258   90.0
  **Cold**                                                                                                                                                                                   
  Sensation                      275                55                  93                             165   75   **0.016**   0.194   284   58   93   168   75   **0.003**   0.196   0.320   77.6
  Unpleasant                     274                55                  2                              164   12   0.052       0.164   284   58   7    168   11   0.338       0.064   0.333   87.6
  Painful                        273                54                  0                              164   5    0.178       0.126   284   58   2    168   6    0.197       0.086   0.477   95.4
  **Touch (brush 1 time)**                                                                                                                                                                   
  Sensation                      288                58                  93                             167   81   0.104       0.142   286   57   93   167   79   **0.017**   0.160   0.264   79.6
  Unpleasant                     288                58                  2                              167   7    0.156       0.095   287   57   2    168   7    0.132       0.100   0.384   93.7
  Painful                        288                58                  0                              167   2    0.234       0.079   287   57   0    168   4    0.148       0.096   0.387   97.3
  **Touch (brush 3 times)**                                                                                                                                                                  
  Sensation                      290                58                  97                             169   85   **0.021**   0.153   289   58   91   169   80   0.055       0.127   0.303   82.7
  Unpleasant                     291                58                  2                              170   7    0.130       0.100   290   58   0    169   12   **0.006**   0.182   0.197   89.4
  Painful                        291                58                  0                              170   2    0.308       0.067   290   58   0    169   5    0.092       0.112   0.351   96.9
  Wind-up                        284                56                  0                              167   8    0.056       0.161   276   50   0    164   12   **0.029**   0.182   0.188   87.1
  **Pricking (safety pin)**                                                                                                                                                                  
  Sensation                      289                58                  95                             168   79   **0.006**   0.183   290   58   91   169   82   0.080       0.116   0.240   79.6
  Unpleasant                     290                58                  19                             169   31   0.180       0.123   290   58   24   169   31   0.298       0.069   0.357   73.4
  Painful                        290                58                  10                             169   20   0.227       0.114   290   58   16   169   21   0.388       0.057   0.286   78.3
  **Pricking (von Frey hair)**                                                                                                                                                               
  Sensation                      289                58                  91                             168   68   **0.003**   0.230   288   57   91   169   68   **0.001**   0.229   0.455   79.0
  Unpleasant                     289                58                  7                              168   14   0.228       0.114   288   58   16   167   20   0.475       0.048   0.329   81.6
  Painful                        289                58                  3                              168   7    0.473       0.081   288   58   12   167   10   0.590       0.036   0.402   90.6
  **Vibration**                                                                                                                                                                              
  Sensation                      291                58                  79                             170   69   0.060       0.157   288   58   81   167   66   0.089       0.147   0.358   73.3
  Unpleasant                     290                57                  5                              170   10   0.528       0.075   290   58   5    169   11   0.275       0.107   0.225   85.4
  Painful                        291                58                  3                              170   8    0.517       0.076   290   58   0    169   7    0.114       0.138   0.435   93.0

**Notes:** Classification of the presence of NePC is based on physicians' assessment of the patient. n, the number of patients; %, the percentage of positive answers (yes) on the questions: Sensation: Is there a sensation?; Unpleasant: Is the sensation unpleasant?; Painful: Is the sensation painful?; *p*-value=*p*-value for statistical significant difference between groups (outcome of chi-square test, *p*≤ 0.05). Bold values are statistically significant (*p*≤0.05).

**Abbreviation:** NePC, neuropathic pain component; V, value of Cramér's V; K, Kappa value; PA, percentage of agreement.

###### 

Patient NASQ values related to physicians' agreement for the presence of an NePC

                       Total group    Congruent outcome by the physicians   Absent NePC      Present NePC     *p*-value                                                                                                                                                                                                                                        
  -------------------- -------------- ------------------------------------- ---------------- ---------------- ---------------- -------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  **Pressure** (kPa)   Summed total   39                                    872 (516;1117)   30               858 (506;1125)   5                                                        846 (729;1086)                                            25                                                        929 (465;1132)                                     0.718[b](#tfn9-jpr-11-1307){ref-type="table-fn"}
  Central              56             866 (542;1068)                        43               872 (545;1058)   15               892 (600;989)                                            28                                                        793 (435;1068)                                            0.558[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  Peripheral           39             794 (526;1084)                        30               793 (516;1095)   5                800 (701;1066)                                           25                                                        787 (488;1106)                                            0.676[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  **CPM**              Positive       23                                    58%              19               61%              3                                                        60%                                                       16                                                        62%                                                0.948[a](#tfn8-jpr-11-1307){ref-type="table-fn"}
  Negative             17             43%                                   12               39%              2                40%                                                      10                                                        39%                                                                                                          
  No change                                                                                                                                                                                                                                                                                                                                                    
  Response             40             131 (−13;225)                         31               109 (3;221)      5                13 (−31;176)                                             26                                                        155 (24;222)                                              0.259[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  CPM value            40             7.2 (−14;25)                          31               7 (−18;23)       5                3 (−19;16)                                               26                                                        8.0 (−16;34)                                              0.591[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  **EPDT** (mA)        Total mean     53                                    11 (7;17)        42               12 (8;17)        16                                                       11 (6;20)                                                 26                                                        12 (8;17)                                          0.969[b](#tfn9-jpr-11-1307){ref-type="table-fn"}
  **CPM**              Positive       13                                    81%              10               40%              8                                                        80%                                                       2                                                         100%                                               0.488[a](#tfn8-jpr-11-1307){ref-type="table-fn"}
  Negative             3              19%                                   2                8%               2                20%                                                      0                                                         ---[c](#tfn10-jpr-11-1307){ref-type="table-fn"}                                                              
  No change                                                                 13               52%                                                                                                                                                                                                                                                               
  Response             16             0.8 (0.03;4)                          12               2 (0.2;5)        10               2 (−0.05;4.0)                                            2                                                         3 (0.4;---)[c](#tfn10-jpr-11-1307){ref-type="table-fn"}   0.747[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  CPM value            16             7.7 (0.3;30)                          12               20 (3;34)        10               15 (−0.2;37)                                             2                                                         26 (18;---)[c](#tfn10-jpr-11-1307){ref-type="table-fn"}   0.667[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  **EPTT** (mA)        Total mean     25                                    10 (8;22)        19               13 (8;23)        3                                                        13 (10;---)[c](#tfn10-jpr-11-1307){ref-type="table-fn"}   16                                                        12 (8;22)                                          0.314[b](#tfn9-jpr-11-1307){ref-type="table-fn"}
  **CPM**              Positive       17                                    68%              13               68%              3                                                        100%                                                      10                                                        63%                                                0.200[a](#tfn8-jpr-11-1307){ref-type="table-fn"}
  Negative             8              32%                                   6                32%              0                ---[c](#tfn10-jpr-11-1307){ref-type="table-fn"}          6                                                         38%                                                                                                          
  No change                                                                                                                                                                                                                                                                                                                                                    
  Response             25             0.5 (−0.2;2)                          19               0.5(−0.2;2)      3                2 (1;---)[c](#tfn10-jpr-11-1307){ref-type="table-fn"}    16                                                        0.4 (−0.3;2)                                              0.117[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  CPM value            25             7 (−2;16)                             19               7 (−2;17)        3                12 (9;---)[c](#tfn10-jpr-11-1307){ref-type="table-fn"}   16                                                        4.8 (−3;16)                                               0.219[b](#tfn9-jpr-11-1307){ref-type="table-fn"}   
  **IWB test**         Latency (s)    41                                    20 (10;170)      32               40 (10;180)      5                                                        40 (10;170)                                               27                                                        40 (10;180)                                        0.960[b](#tfn9-jpr-11-1307){ref-type="table-fn"}

**Notes:** Classification of presence of NePC is based on physicians' assessment of the patients. Absent, NePC is absent; Present, NePC is present; Undetermined, both physicians disagree with each other about the existence of an NePC; N, number of patients in the analysis; CPM \> ±10%: patients included in the analysis with a CPM of more than 10% difference from zero.

Chi-square test;

Mann--Whitney *U*-test. *p*≤0.05 is considered statistically significant;

due to the low number of patients in the analysis, IQR is not given in the 75% range.

**Abbreviations:** NASQ, Nijmegen--Aalborg screening quantitative sensory testing; NePC, neuropathic pain component; CPM, Conditioned pain modulation; EPDT, electrical pain detection threshold; EPTT, electrical pain tolerance threshold; IWB, ice water bucket; IQR, interquartile range.
